A study investigating the ability of OCTA imaging technology to identify and analyze
untreated type 1, 2, and 3 neovascular membrane lesions in treatment naive patients with
exudative macular degeneration, as well as investigating the ability of the OCTA imaging
technology to evaluate the treatment outcomes of Intravitreal Aflibercept Injection in
neovascular lesions associated with macular degeneration.
This study is utilizing a new, FDA approved, non-standard of care technology (OCT-Angiography
by Optovue) to image and evaluate the treatment outcomes of using standard of care
Intravitreal Aflibercept Injections for their approved use in patients diagnosed with
neovascular AMD who are naive to previous Anti-VEGF therapies.